iron clinical
trial published.

>Your< Iron Syrup is now clinically proven to increase ferritin levels in iron-deficient children by 69%, thus enabling them to avoid anemia. The study, published in MDPI Nutrients, is the first to show anemia in iron-deficient children can be avoided through supplementation.

Results overview:

  • >Your< Iron Syrup improved mean ferritin levels by 69% (14,5 μg/l -> 24,5μg/l) – to levels significantly above the threshold at risk of anemia (20 μg/l)
  • the test group also showed significantly higher hemoglobin (p=0,02), hematocrit (p=0,02), and erythrocyte levels (p=0,03)
  • compliance was 92% and there were 0 severe adverse events confirmed to be related to supplementation
  • there was no significant difference in compliance or adverse events between the test group and placebo
  • 85 children completed the trial and gold standards of clinical trial design were upheld


Download to access the details on the trial, its results, and the business opportunity.

Business reasons.

What kind of business opportunity does iron present? Why is it overlooked? And why our investment into a clinical trial? Blaž Gorjup (Chairman & Founder) and Matevž Ambrožič (Marketing & PR Director) speak about the business reasons behind PharmaLinea’s most recent research project.

To answer increased demand, our partners have been successfully launching both our dedicated vitamin D3 products and >Your< Immuniq Line products, which contain vitamin D3. With a short time to market and clear product differentiation, our vitamin D3 products were well received in different markets and their turnover has tripled in 2020. View the presentation below to see how we can support you in addressing the vitamin D market.

reach out.

  • Max. file size: 30 MB.

PharmaLinea © 2024